Serum nξ-(carboxymethyl)lysine is elevated in nondiabetic coronary heart disease patients

Journal of Basic and Clinical Physiology and Pharmacology

Volumn 13, Issue 3, 2002, Pages 201-214

  Dworacka, Marzena ^a   Winiarska, Hanna ^a   Szymanska, Malgorzata ^a   Szczawiriska, Krystyna ^a   Wierusz Wysocka, Bogna ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b F Raszeja Hospital   (Poland)

Author keywords

C peptide; glycoxidation; HDL cholesterol; lipoxidation

Indexed keywords

6 N CARBOXYMETHYLLYSINE; C PEPTIDE; HIGH DENSITY LIPOPROTEIN; DRUG DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LYSINE; N(6) CARBOXYMETHYLLYSINE; N(6)-CARBOXYMETHYLLYSINE;

ARTICLE; ATHEROSCLEROSIS; CELL ACTIVITY; CONCENTRATION RESPONSE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; GLYCATION; IMMUNOREACTIVITY; ISCHEMIC HEART DISEASE; MEASUREMENT; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; ARTERIOSCLEROSIS; BLOOD; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIPID METABOLISM; MALE; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; PANCREAS ISLET;

ARTERIOSCLEROSIS; C-PEPTIDE; CARBOHYDRATE METABOLISM; CHOLESTEROL, HDL; CORONARY DISEASE; DIABETES MELLITUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE; HUMANS; ISLETS OF LANGERHANS; LIPID METABOLISM; LIPOPROTEINS, HDL; LYSINE; MALE; MIDDLE AGED; OXIDATION-REDUCTION;

EID: 0036955007     PISSN: 07926855     EISSN: 21910286     Source Type: Journal    
DOI: 10.1515/JBCPP.2002.13.3.201     Document Type: Article

References (19)

1. Baynes, JW, Thorpe, SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1–9.
2. Fu, MX, Requena, JR, Jenkins, AJ, Lyons, TJ, Baynes, JW, Thorpe, SR. The advanced glycation end product, Nξ-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996; 271: 9982–9986.
3. Vlassara, H, Bucala, R, Striker, L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994; 70: 138–151.
4. Kume, S, Takeya, M, Mori, T, Araki, N, Suzuki, H, Horiuchi, S, et al. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol 1995; 147: 654–657.
5. Sakata, N, Imanaga, Y, Meng, J, Tachikawa, Y, Takebayashi, S, Nagai, R, Horiuchi, S. Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease. Atherosclerosis 1999; 142: 67–77.
6. Stitt, A, He, C, Friedman, S, Scher, L, Rossi, P, Ong, L, et al. Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Mol Med 1997; 3: 617–627.
7. Ryan, TJ, Antman, EM, Brooks, NH, Califf, RM, Hillis, LD, Hiratzka, LF, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999; 34: 890–911.
8. Polish Cardiac Society. Ischemic heart disease. Standards for the management in the diseases of circulatory system. Kardiol Pol Suppl 1 1997; 46: 5–18.
9. Makita, Z, Vlassara, H, Cerami, A, Bucala, R. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992; 267: 5133–5138.
10. Recommendations for the management of type 2 diabetes mellitus in the Central, Eastern and Southern European Region. Consensus statement. Int J Postgrad Train Med 2000; 8: 3–26.
11. European Atherosclerosis Society, International Task Force for the Prevention of Coronary Heart Disease. Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis 1992; 2: 113–156.
12. Hogan, M, Cerami, A, Bucala, R. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest 1992; 90: 1110–1115.
13. Kunt, T, Forst, T, Harzer, O, Buchert, G, Pfützner, A, Löbig, M, et al. The influence of advanced glycation endproducts (AGE) on the expression of human endothelial adhesion molecules. Exp Clin Endocrinol Diabetes 1998; 106: 183–188.
14. Yamagishi, S, Fujimori, H, Yonekura, H, Yamamoto, Y, Yamamoto, H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia 1998; 41: 1435–1441.
15. Bucala, R, Makita, Z, Koschinsky, T, Cerami, A, Vlassara, H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993; 90: 6434–6438.
16. Yan, SD, Schmidt, AM, Anderson, GM, Zhang, J, Brett, J, Zou, YS, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889–9897.
17. Hedrick, CC, Thorpe, SR, Fu, MX, Harper, CM, Yoo, J, Kim, SM, et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000; 43: 312–320.
18. Johansson, BL, Linde, B, Wahren, J. Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of type 1 (insulin-dependent) diabetic patients. Diabetologia 1992; 35: 1151–1158.
19. Forst, T, De La Tour, DD, Kunt, T, Pfutzner, A, Goitom, K, Pohlmann, T, et al. Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na+, K+-ATPase activity in diabetes mellitus type I.Clin Sci (Lond) 2000; 98: 283–290.